SUMMARY We directly measured the net pulmonary extraction of circulating norepinephrine, epinephrine and dopamine in control patients and patients with primary or secondary pulmonary hypertension. Mixed pulmonary artery norepinephrine, epinephrine and dopamine were 314 ± 13 pg/ml, 102 ± 9 pg/mI, 51 ± 5 pg/mi, respectively, for the control group; values were similar in patients with pulmonary hypertension. The pulmonary extraction of norepinephrine was 25.4 ± 2.6% (clearance 266 ± 62 ng/min) in control patients; epinephrine and dopamine were not extracted. There was no net extraction or production of any of the three catecholamines by the lungs in any of the patients with pulmonary hypertension. We conclude that the lungs play a significant role in the inactivation of circulating norepinephrine in man. This metabolic function of the lungs appears to be lost in pulmonary hypertension.
THE LUNGS PARTIALLY INACTIVATE many bloodborne, vasoactive compounds during their passage through the pulmonary circulation.' 3 Studies of the pulmonary extraction of the biogenic amines, particularly norepinephrine, have been performed either in isolated, perfused lung preparations3-5 or in vivo by indirect means.6' The extent to which the lungs participate in the removal of endogenous, circulating norepinephrine, epinephrine and dopamine has not been directly measured in man. Recently, Sole and Hussain8 described a specific, sensitive, radioenzymatic assay for the simultaneous measurement of norepinephrine, epinephrine and dopamine in plasma. Using this technique, we examined the net extraction of these three catecholamines by the human lung in resting, unanesthetized volunteers.
Studies in the isolated perfused lung have shown that the uptake of monoamines is mediated by pulmonary vascular endothelial cells. 4 ' Because pulmonary vascular disease may affect this aspect of lung function, we also examined several patients with documented pulmonary hypertension.
Methods
We studied 24 patients undergoing cardiac catheterization. No patient received sympathetic agonists or antagonists for 72 hours before the study. Patients fasted for 16 hours before catheterization. Right-and left-heart catheterization was performed by percutaneous techniques from the right groin. The arterial catheter was left in the descending aorta; the right-heart catheter was positioned in the main pulmonary artery. After an undisturbed period of 10 minutes, simultaneous aortic and pulmonary artery blood samples were obtained for the catecholamine assay. We then determined cardiac output by thermodilution or the Fick method, recorded blood pressures, and repeated the blood sampling. The entire evaluation preceded the injection of any angiographic contrast material.
Plasma norepinephrine, epinephrine and dopamine were assayed radioenzymatically as described by Sole and Hussain. 8 We found that catecho-0-methyl transferase (COMT) preparations may vary with each new preparation of COMT enzyme stock; thus, we determined the optimum amount of enzyme and the corresponding amount of benzyloxyamine to include in the incubation medium when new enzyme was prepared.
Data are given as mean ± SEM. The statistical significance of differences between groups was determined by t test.
Results
The cardiac diagnostic classification and hemodynamic characteristics of our patients are given in table 1. We performed pulmonary function tests in all but four patients, who had no suggestion of pulmonary disease, and were normal except for some increase in airway obstruction in five of the patients who had an increase in left atrial pressure. Eleven patients smoked more than 10 cigarettes daily. Six of the patients with normal pulmonary vascular resistance and five of the patients with pulmonary hypertension were taking digoxin.
The results of the catecholamine determinations for the control group and the pulmonary hypertensive group are summarized in table 2. There was no difference in pulmonary artery norepinephrine concentration between the normotensive and pulmonary hypertensive groups. There was a 25.8% decrease in aortic norepinephrine (relative to pulmonary artery norepinephrine) in the normotensive group. There was no difference between pulmonary artery and aortic 160 figure 1 . A history of smoking or an elevation of left atrial pressure and mean pulmonary artery pressure in the absence of an increase in pulmonary vascular resistance did not affect the removal of norepinephrine. The lungs extracted 25.4 ± 2.6% of circulating norepinephrine in the normotensive group; in patients with pulmonary hypertension the extraction was 0.02 ± 1.5%. The difference between the two groups was significant (p < 0.001). There were no features that distinguished the two patients with pulmonary vascular resistances less than 4 (1.5 resistance units (RU), 2.5 RU) who failed to show a net extraction of norepinephrine. The patient with marginal pulmonary hypertension who had a "normal" net extraction of norepinephrine had a pulmonary vascular resistance of 2.9 RU. Discussion We have shown, by direct measurement, that approximately 25% of circulating norepinephrine is extracted during passage through the lungs in resting man. The catecholamine inactivation process appears to be selective for norepinephrine, as neither epinephrine nor dopamine were affected by their passage through the pulmonary circulation. These data support earlier observations indirectly derived from isolated, perfused lungs, animal models and man. 1 7 The pulmonary inactivation of norepinephrine appears to be mediated by a temperature-sensitive, sodium-dependent, saturable, facilitated transport process found in the endothelial cells of pre-and post- capillary vessels and pulmonary veins.4 I Uptake by nerve endings is negligible.5 After uptake, norepinephrine is rapidly degraded by monoamine oxidase and COMT and the metabolites are released.5 Since the lungs are strategically situated to receive the total circulating blood volume, the pulmonary modification of systemic levels of circulating norepinephrine (in contrast to epinephrine and dopamine) must be of some physiological importance.9
The net removal of norepinephrine by the lungs in our control patients ranged from 120-1,040 ng/min. pulmonary hypertension has long been sought. There are reports, however, that suggest that norepinephrine can produce an increase in pulmonary vascular resistance.'0-"9 Furthermore, Fishman"0 offers the suggestion that injury of the pulmonary vascular endothelium, with impairment of the pulmonary inactivation of vasoactive substances, may result in further or self-perpetuating damage to the pulmonary vasculature. Thus, it would be interesting to examine relatives of patients with familial, primary pulmonary hypertension to determine whether a defect in norepinephrine extraction antedates the development of the increase in pulmonary vascular resistance.
